Zydelig is already approved to treat chronic lymphocytic leukemia, but it's limited to treatment in combination with Rituxan when other drugs aren't appropriate. The expanded market should help Gilead -- and Teva Pharmaceuticals, Biogen, and Roche -- sell more of their drugs. Gilead plans to ask regulators in the U.S. and EU to update the label with the new data early next year.
Teva Pharmaceuticals, Biogen, and Roche shouldn't get too excited about the potential bump in sales from Gilead Sciences' good data, though. Gilead is testing Zydelig as a first-line treatment before Treanda and Rituxan would be used, potentially making the triple combination obsolete fairly soon after it's approved.
Potential swift kick in the butt.....upwards.....should it be approved as a stand alone drug